Atea Pharmaceuticals (AVIR) Receivables - Other (2020)

Atea Pharmaceuticals' (AVIR) quarterly Receivables - Other came in at $5.8 million in Q4 2020.

Atea Pharmaceuticals (AVIR) Receivables - Other (2020) Analysis & Trends

Atea Pharmaceuticals' Receivables - Other history runs 1 years deep, the most recent figure standing at $5.8 million for Q4 2020.

  • On a quarterly basis, Receivables - Other changed N/A year-over-year to $5.8 million in Q4 2020; TTM through Dec 2020 was $5.8 million, a N/A change from a year earlier, with the FY2020 full-year figure at $5.8 million, changed N/A from the prior year.
  • Receivables - Other steadied at $5.8 million in Q4 2020 per AVIR's latest filing.
  • Across five years, Receivables - Other topped out at $5.8 million in Q4 2020 and bottomed at $5.8 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Atea Pharmaceuticals 376.19 Mn 376.19 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 5.82 Mn
Dec 31, 2020 5.82 Mn